Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT06921239
Recruiting Observational

HLA Antibodies in Systemic Lupus Erythematosus

NCT06921239 · tracked via the Priya Life Science France tracker
Sponsor
Centre Hospitalier Universitaire, Amiens
Phase
Observational
Started
2025-02-10
Last updated
2026-01-16

Condition(s) studied

HLA AntibodiesSystemic Lupus Erythematosus

Study summary

Patients suffering from autoimmune diseases show false-positive results when anti-HLA antibodies are identified. This false positivity makes it difficult to obtain an organ transplant based on immunological compatibility (absence of anti-HLA antibodies directed against graft antigens). The objectives of this project are to study the prevalence of these false positivities in a population of lupus patients, and to evaluate biological tests that can negate these false positivities.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients Adults * Followed in the internal medicine department of Amiens University Hospital - With systemic lupus erythematosus * Without HLA immunization risk factors (no history of pregnancy, transfusions or transplants) * With sera stored in the biobank Exclusion Criteria: * minor Patients * Opposing the re-use of their personal data for research purposes

Primary outcome measure(s)

  • prevalence of unexplained antibody positivity — 6 months
    prevalence of unexplained antibody positivity

Trial sites (1)

FacilityCityRegionStatus
CHRU Amiens Amiens France Recruiting

More Centre Hospitalier Universitaire, Amiens trials in France

The Clinical and Hemodynamic Course of Cardiogenic Shocks Hospitalized in Critical Care Recruiting
Prevalence and Clinical Significance of Anti-annexin A2 Antibodies in COVID-19 Infection Recruiting
Induced Membrane Properties in Children and Adults Recruiting
Phonological Constraints on Language Development in Individuals With Williams Syndrome Recruiting
Place of Nasogastric Tube in Uncomplicated Adhesive Small Bowel Obstruction Recruiting

Other trials for the same condition

A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE) Active, not recruiting
Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2) Active, not recruiting
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus Active, not recruiting
A Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD) Recruiting
A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE), Sjogren's Disease (SjD) and Rheumatoid Arthritis (RA) Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06921239 on ClinicalTrials.gov ↗ ← All trials in France